After prostate surgery, men whose PSA levels drop to almost nothing (below 10 ng/L) are much less likely to have the cancer come back or die from it than those whose PSA stays higher.

40

Pro

0

Against

Evidence from Studies

Supporting (1)

40

Community contributions welcome

40

Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review

Systematic Review

Human

2024 Apr 8

This study found that men with prostate cancer who have very, very low PSA levels after surgery are much less likely to have the cancer come back and are more likely to live longer — which matches what the claim says.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review

Score: 40

DOI: 10.3390/biomedicines12040822

Similar Assertions

If radiation therapy brings the PSA level back to undetectable after cancer comes back, the patient is much more likely to live longer—even if the PSA was already high when treatment started.

40

0

83%

Testing men for prostate cancer with PSA blood tests might save a few lives, but it often finds cancers that would never cause harm, leading to unnecessary treatments with side effects.

1

0

71%

Prostate-specific antigen (PSA) levels in serum serve as a biomarker for prostate tissue abnormality, enabling detection of early-stage prostate cancer in asymptomatic individuals when anatomical obstruction has not yet occurred.

40

0

71%